Abstract：Objective To assess the value of serum anti-aspergillus IgG antibody in predicting the prognosis of patients with chronic pulmonary aspergillosis (CPA).Methods The clinical data on 27 cases of chronic pulmonary aspergillosis treated between March 2017 and February 2019 was retrospectively analyzed. According to their conditions 90 days after treatment, these patients were divided into the improvement group (19 cases) and progress group (8 cases). After admission, all the patients were assessed in terms of Acute Physiology and Chronic Health Evaluation II (APACHEII) scores for the first 24 hours. Serum aspergillus specific IgG antibody was detected by ELISA, and blood routine test, serum-G and serum-GM test were conducted. APACHEII scores, white blood cell count, neutrophil count, platelet count, C-reactive protein (CRP), procalcitonin (PCT), serum-G, serum-GM assay and aspergillus specific IgG antibody levels were compared between the two groups after admission. The predictive value for prognosis was determined.Results There was no significant difference in APACHEII scores between the two groups during the first 24 hours of admission. After admission, the levels of leukocyte count, neutrophil, platelet count, CRP, PCT, serum-G and serum-GM assay in these two groups were similar. The serum specific IgG level in the progress group was (178.8±24.6)AU/ml, which was significantly higher than that of the improvement group (122.3±19.5) AU/ml (t=-3.625,P＜0.05).Conclusions Serum aspergillus specific IgG can be used as a useful prognostic indicator of prognosis for patients with chronic pulmonary aspergillosis.
Hope W W, Walsh T J, Denning D W. The invasive and saprophytic syndromes due to Aspergillus spp[J]. Med Mycol,2005,43(Suppl.1): S207-238.
[2]
Denning D W. Chronic forms of pulmonary aspergillosis[J]. Clin Microbiol Infect 2001;7 (Suppl.2):25-31.
[3]
Denning D W, Cadranel J, Beigelman-Aubry C, et al. Chronic pulmonary aspergillosis:rationale and clinical guidelines for diagnosis and management[J]. Eur Respir J, 2016, 47(1):45-68.
Denning D W, Pleuvry A, Cole D C. Global burden of chronic pulmonary aspergillosis complicating sarcoidosis[J]. Eur Respir J.2013,41(3):621-626.
[6]
Denning D, Pleuvry A, Cole D. Global burden of chronic pulmonary aspergillosis as a sequel to pulmonary tuberculosis[J]. Bull World Health Organ, 2011, 89(12):864e72.
[7]
Agarwal R, Dua D, Choudhary H, et al. Role of Aspergillus fumigatus-specific IgG in diagnosis and monitoring treatment response in allergic bronchopulmonary aspergillosis[J]. Mycoses,2017, 60(1):33-39.
[8]
Denning D W, Cadranel J, Beigelman-Aubry C, et al. Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management[J].Eur Respir J, 2016,47:45-68.
[9]
Patterson T F, Thompson G R, Denning D W, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America[J]. Clin Infect Dis,2016,63(4):e1-e60.
Jhun B W, Jeon K, Eom J S, et al. Clinical characteristics and treatment outcomes of chronic pulmonary aspergillosis[J]. Med Mycol, 2013,51(8):811-817.
[12]
Shin B, Koh W J, Jeong B H, et al. Serum galactomannan antigen test for the diagnosis of chronic pulmonary aspergillosis[J].J Infect, 2014,68(5):494-499.
Izumikawa K, Yamamoto Y, Mihara T, et al. Bronchoalveolar lavage galactomannan for the diagnosis of chronic pulmonary aspergillosis[J]. Med Mycol,2012,50(8):811-817.
[18]
Barton R C, Hobson R P, Denton M, et al. Serologic diagnosis of allergic bronchopulmonary aspergillosis in patients with cystic fibrosis through the detection of immunoglobulin G to Aspergillus fumigatus[J]. Diagn Microbiol Infect Dis, 2008, 62(3):287-91.
[19]
Uffredi M L, Mangiapan G, Cadranel J, et al. Significance of Aspergillus fumigatus isolation from respiratory specimens of nongranulocytopenic patients[J]. Eur J Clin Microbiol Infect Dis,2003,22:457-462.
2020, Vol. 31 
